Nrf2 activator, trans-resveratrol and hesperetin combination, corrected glycolytic overload and insulin resistance clinically and now merits evaluation for early-stage treatment of MASLD. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatotic liver disease.